Degradation of human apolipoprotein B-100 by apolipoprotein(a)  by Chulkova, T.M. & Tertov, V.V.
Volume 336, number 2, 327-329 FEBS 13425 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
December 1993 
Degradation of human apolipoprotein B-100 by apolipoprotein(a) 
T.M. Chulkova”**, V.V. Tertovb 
‘Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Pogodinskaya st. 10, Moscow, Russian Federation 
bInstitute of Experimental Cardiology, Cardiology Research Center, Moscow, Russian Federation 
Received 29 October 1993 
Human plasma low density lipoproteins (LDL) contain a very high molecular weight protein termed apoB-100 (MC = 550,000). In many samples 
of LDL, minor components designated as apoB-74 (M, = 407,000) and apoB-26 (M, = 145,000) are present. It has been shown that they can arise 
as a result of proteolytic degradation of apoB-100. Our earlier studies demonstrated that the active forms of lipoprotein(a) (LP(a)) and apolipopro- 
tein(a) (ape(a)) possess proteolytic activity. In the present study we investigated the possibility of apoB-100 degradation in the presence of activated 
ape(a). LDL were incubated with the puritkd ape(a) and analyzed by SDS-polyacrylamide gel electrophoresis. It was found that apoB is cleaved 
by ape(a) with formation of proteolytic fragments including B-74 and B-26. The physiological significance of apoB degradation under the action 
of ape(a) is considered. 
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1. INTRODUCTION 
Apolipoprotein B-100 (apoB-100) is a major protein 
of plasma low density lipoproteins (LDL). ApoB-100 
plays a key metabolic role in its function as a ligand for 
high affinity receptors on cell membranes, which endo- 
cytose LDL to provide sterol for membranes biogenesis 
and hormone synthesis [l]. 
responsible for the degradation of apoB-100. The pres- 
ent study was undertaken to clarify whether ape(a) is 
capable of cleaving apoB- 100. 
2. EXPERIMENTAL 
The apparent molecular weight of apoB-100 by so- 
dium dodecylsulfate (SDS) electrophoresis has been re- 
ported to be 550,000. Kane et al. [2] have reported the 
presence of smaller fragments of apoB in LDL and 
designated these fragments as B-100, B-74 and B-26. 
Significant amounts of B-74 and B-26, which may be 
complementary constituents of B-100, have been de- 
tected in the LDL of many individuals. At present, the 
origin and physiological significance of B-74 and B-26 
are unknown, although it has been shown that they can 
arise during blood collection as a result of proteolytic 
degradation. It was found that kallikrein can degrade 
apoB-100 and produce B-74 and B-26 [3]. 
A lipoprotein fraction @ = 1.05-l. 12 g/ml), including lipoprotein(a) 
was isolated from human pooled Lp(a) positive plasma containing 
EDTA (1 mM) and sodium azide (0.01%) by density gradient ultracen- 
trifugation (40,000 rpm, for 20 h, at 14”C, in Beckman 40.3 rotor) [7]. 
LDL were isolated by ultracentrifugation between densities of 1.02 
and 1.05 g/ml. 
Ape(a) was prepared from isolated lipoproteins ofp = 1.12 g/ml by 
the method of Fless et al. [8]. Lipoproteins (5-10 mgknl in 0.05 M 
Tris-HCl, pH 7.4) were treated with dithiothreitol(l0 mM) for 1 h at 
37°C. The solution was brought to a density of 1.12 g/ml and was 
centrifuged for 20 h at 14°C and 40,000 rpm. Remnant lipoprotein 
particles, containing apoB were recovered from floating layers at the 
top of the tubes. The infranatant fluids which contained ape(a) were 
pooled and purified by ultrafiltration using Amicon XM-300 mem- 
brane. 
The purified ape(a) was displayed as a single band of molecular 
weight of more than 550,000 on SDS-polyacrylamide gel electrophore- 
sis (Fig. 1A). 
All human plasmas contain a variant of LDL called 
lipoprotein(a) (Lp(a)). Lp(a) consist of apoprotein B 
plus an additional specific antigen called apoprotein(a) 
(ape(a)) [4]. The ape(a) is covalently linked to apoB via 
disulfide bridges [5]. 
Recently we have found that Lp(a) after treatment 
with trypsin-Sepharose or collagen-Sepharose pos- 
sessed proteolytic activity [6]. The active form of Lp(a), 
as well as active ape(a), can split some synthetic sub- 
strates and active plasma prekallikrein to kallikrein. 
Based on these results, we suggested that ape(a) may be 
*Corresponding author. 
Ape(a) was assayed for a amidolytic activity using the fluorogenic 
substrate benzyloxycarbonyl-L-phenylalanyl-L-agrinou- 
maryl-7-amide (Cbz-Phe-Arg-MCA). Ape(a) (100 ~1) in 0.05 M Tris- 
HCl, pH 7.4, was incubated with 10 ~1 of 1 mM Cbz-Phe-Arg- MCA 
at 37°C for 10 min. The reaction was stopped by addition of 50 ~1 of 
50% acetic acid, and the increase in fluorescence of the leaving group 
7-aminoA-methylcoumarine was determined from the fluorescence 
emission (460 nm), excitation at 370 nm, using Opton fluorescence 
spectrophotometer. The specific activity was the amount of substrate 
hydrolyzed per min per mg of ape(a) at 37°C. The amount of 7-amino- 
4-methylcoumarin released was read from a 7-amine-4- meth- 
ylcoumarin calibration curve. In order to determine the degradation 
of apoB-100 by ape(a), LDL containing predominantly apoB-100 
were incubated with ape(a) and the degradation products were ana- 
lyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). SDS- 
PAGE was performed on 5% homogeneous lab gels employing the 
buffer system of Laemmli [9]. 
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A sample of LDL, containing 0.1 mg of protein in 0.1 ml of 0.05 
M Tris-HCl, pH 7.4, was combined with 0.01 mg of ape(a) and 
incubated for 5 min, 30 min, and 3 h at 37’C. As control was used 
LDL incubated for 3 h at 37°C in 0.05 M Tris-HCl, pH 7.4, without 
ape(a). The enzymatic reaction was terminated by mixing the samples 
(20 ~1) with electrophoresis sample buffer of final composition 60 mM 
Tris-HCl, pH 6.8, 1% SDS, 5% 2-mercaptoethanol, 20% sucrose, and 
0.03% Bromophenol blue. Prior to electrophoresis, the samples were 
boiled for 1 min. The gels were stained with Coomassie brilliant blue 
R-250. The protein standards were ferritin (440,000 and 220,000), 
phosphorylase b (94,000), bovine serum albumin (68,000), ovalbumin 
(45,000). 
Protein concentration was determined by the method of Lowry 
using bovine serum albumin as a standard [lo]. 
3. RESULTS AND DISCUSSION 
The purified preparation of ape(a) had an initial spe- 
cific activity of 0.5 nmol/min/mg. Storage at 7°C (in the 
refrigirator) led to the activation of ape(a). The ape(a) 
kept in the cold for two weeks and having a specific 
activity of 20 nmol/min/mg was used in our experi- 
ments. When LDL was incubated with ape(a) and elec- 
trophoresed on SDS-PAGE, fragments of apoB-100 
were observed with apparent molecular weights corre- 
sponding to B-74 and B-26, as well as other fragments 
with molecular weights in the range of 220,000, 80,000, 
60,000, and 40,000. (Fig. lB, lanes c-e). The predomi- 
nant proteolytic products initially observed were pep- 
tides with apparent molecular weights 400,000,220,000, 
60,000, and 40,000 (Fig. lB, lanes c,d). After 3 h incu- 
bation, apoB-100 was virtually absent (Fig. lB, lane e). 
The control LDL, incubated at 37°C for 3 h without 
ape(a), showed no degradation (Fig. lB, lane b). This 
rules out the presence of lipoprotein-associated pro- 
tease(s) contaminant. Therefore, the degradation of 
apoB was due to the ape(a)-caused proteolysis. 
The enzymatic properties of the active form of ape(a) 
_ its substrate specificity, relation to inhibitors, ability 
to activate plasma prekallikrein [6] - provide evidence 
that ape(a) is a new plasma proteinase. The presently 
known activator of plasma prekallikrein (factor XIIa) 
differs from ape(a) by its physico-chemical properties 
and relation to inhibitors. The structure of ape(a) was 
established in 1987 [ll] but its enzymatic activity and 
function remained obscure. The results of our earlier 
and present experiments howed that ape(a) is a zymo- 
gen. Catalytically active ape(a) can convert plasma pre- 
kallikrein to kallikrein and degrade apoB-100. Charac- 
teristically, apoB-100, the ligand for LDL receptor, oc- 
curs in the circulation being covalently bound to the 
proenzyme, the activation of which leads to the degra- 
dation of apoB-100. It is likely that specific linkage of 
ape(a) to apo-B has physiological significance. It may 
well be suggested that concurrently proceeding plasma 
kallikrein activation and apoB hydrolysis have a role in 
the regulation of the uptake and metabolism of lipopro- 
teins by some type of cells, e.g. by granulose (ster- 
oidogenic) cells, which have CAMP-mediated mecha- 
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Fig. 1. SDS-PAGE analysis: (A) purhled ape(a); (B) degradation of 
apoB-100 by ape(a). (Lane a) Standard proteins used as molecular 
mass markers: (1) fenitin (220,000); (2) phosphorylase b (94,000); (3) 
bovine serum albumin (68,000); (4) ovalbumin (43,000). (Lane b) Con- 
trol LDL. (Lanes c-e) LDL (0.1 mg apoB-100) at various times (5 min, 
30 min, 180 min) after incubation with ape(a) (0.1 mg). 20 fig of 
protein were electrophoresed in 5% PAG, containing 0.1% SDS. Ex- 
perimental details are given in the text. 
nism for regulation of LDL receptor synthesis [12]. 
Bradykinin released by kallikrein is known to stimulate 
CAMP formation [13]. 
It is as yet unclear how and when the activation of 
ape(a) of Lp(a) occurs in vivo and what its physiologi- 
cal significance really is. It is apparent, however, that 
disturbances in the regulation of ape(a) activity may 
lead to such pathological consequences as thrombosis 
and atherosclerosis. 
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